Focus on Nintedanib in NSCLC and other tumors

Focus on Nintedanib in NSCLC and other tumors

Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptors and fibroblast growth factor (FGF) receptors. Evidence about its efficacy in addition to...

Full description

Bibliographic Details
Main Authors: Anna Manzo, Guido Carillio, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Gaetano Rocco, ALESSANDRO MORABITO
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-12-01
Series:Frontiers in Medicine
Subjects:
Angiogenesis Inhibitors
VEGF
review
NSCLC
Nintedanib
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmed.2016.00068/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fmed.2016.00068/full

Similar Items